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Abstract
The European Commission requested EFSA assess antimicrobial-resistant bacteria responsible for
animal transmissible diseases, with a view to listing such pathogens for European Union action. This
Scientific Opinion addresses the ad hoc method developed: (i) to give a global state of play as regards
resistant animal pathogens that cause transmissible animal diseases, (ii) to identify the most relevant
bacteria in the EU and (iii) to summarise their actual or potential animal health impact, and to perform
their assessment for being listed and categorised according to the criteria of Articles 7, 5, 9 and 8
within the Animal Health Law (AHL) framework. An extensive literature review is carried out to give the
global state of play of selected resistant bacteria that constitute a threat to animal health (i). An expert
judgement procedure, based on the outcome of the literature review, is applied to identify which
among those bacteria subjected to the literature review are the ‘most relevant’ in the European Union
(ii). Their animal health impact in the European Union and their assessment for being listed and
categorised according to the AHL framework will follow the ‘ad hoc method for the assessment on
listing and categorisation of animal diseases within the framework of the Animal Health Law’ that EFSA
has developed in the past (iii). The assessment of (i) and (ii) is addressed in distinct scientific opinions
that are published separately by animal species of interest (dogs and cats, horses, pigs, poultry, cattle,
small ruminants, rabbits and aquatic animal species). The assessment of (iii) is addressed in distinct
scientific opinions and published separately by the animal pathogen.
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1. Introduction
The Regulation (EU) 2016/429 on transmissible animal diseases (‘Animal Health Law’),1 from this
point forward referred to as AHL, requires the Commission to list any disease after a completed
assessment of that disease in accordance with the set of criteria provided for in the AHL. In the past
years EFSA was asked several times to provide, and subsequently delivered, scientific opinions on the
assessment of many diseases in animals, on the listing and categorisation of those diseases in
accordance with the AHL. Parallel to this, the Commission adopted a European One Health Action Plan
against Antimicrobial Resistance (AMR) in 2017, in which it committed to ‘identify and assess under the
AHL and with the support of EFSA, resistant bacteria that cause transmissible diseases and, if
necessary, develop harmonised rules for their surveillance’.
1.1. Background as provided by the requestor
Provisions for the monitoring of antimicrobial resistance (AMR) in zoonotic and indicator bacteria
are laid down in Directive 2003/99/EC2. Commission Implementing Decision 2013/652/EC3,
implementing that Directive, lays down detailed and harmonised rules for the monitoring and reporting
of AMR in those bacteria. It is currently being revised, with an adoption foreseen for summer 2020.
This legislative framework has been based on, and associated with, several past EFSA scientific
outputs. Recently, EFSA published new Technical specifications on harmonised monitoring of
antimicrobial resistance in zoonotic and indicator bacteria from food- producing animals and food.4
There are no harmonised EU rules for the surveillance of AMR in bacteria, which cause transmissible
animal diseases in animals, but not in humans. Indeed, before the AHL entered into force, the lack of
suitable EU legal basis did not allow the establishment of specific rules for such EU-wide surveillance.
Former AMR-related mandates to EFSA focused on AMR in food-borne bacteria in relation to their
public health importance, although an EFSA-EMA joint scientific opinion also reviewed circumstances
and diseases in which antimicrobials are most intensively used in food-producing animals and related
examples of development of AMR.5 In addition, EMA has provided advice on the impact on public
health and animal health following the use of antimicrobials in animals.6 This advice is being updated
and should be finalised by the end of 2019/beginning of 2020.
There are relevant international standards, such as the Codes of the World Organisation for Animal
Health (OIE), which provide guidance on the conduction of AMR monitoring and surveillance
programmes in food-producing animals and list a number of bacterial pathogens as potentially to be
included in a monitoring programme in food-producing animals. However, the relevant Chapter 6.8 of
the Terrestrial Code7 (Article 6.8.5. point 1, Table 2) does not provide an exhaustive list and in
particular that point 1 and Table 2 contains only a few bacterial pathogens of animals (the focus of the
current mandate) as examples. The corresponding Chapter 6.4. of the Aquatic Code8 (Article 6.4.5.)
lists only zoonotic bacteria as a minimum to be included in a monitoring programme.
In recent years, EFSA has been closely associated with the Commission services task aimed at the
revision of the list of transmissible animal diseases in Annex II to the AHL, which will be applicable
from April 2021. That included their thorough assessment against the specific criteria in the AHL and
EFSA developed a methodology to contribute to that assessment.
Against this background, the Commission wishes to further explore this area, understand its state
of play, and to the extent possible, explore emerging issues as regards AMR in bacteria responsible for
transmissible animal diseases, with a view of listing such pathogens for EU action. The focus of this
exercise is on resistant bacterial animal pathogens causing transmissible diseases excluding those
already covered by Directive 2003/99/EC. The collection of such resistance data will provide a more
1 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0429&rid=8
2 Directive 2003/99/EC of the European Parliament and of the Council of 17 November 2003 on the monitoring of zoonoses and
zoonotic agents, amending Council Decision 90/424/EEC and repealing Council Directive 92/117/EEC, OJ L 325, 12.12.2003, p. 31.
3 Commission Implementing Decision of 12 November 2013 on the monitoring and reporting of antimicrobial resistance in zoonotic
and commensal bacteria (notified under document C(2013) 7145) Text with EEA relevance, OJ L 303, 14.11.2013, p. 26.
4 EFSA Journal 2019;17(6):570, https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2019.5709
5 E.g. EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry






Assessment of animal diseases caused by bacteria resistant to antimicrobials: ad hoc method
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2021;19(6):6645
complete picture of antimicrobial resistance in animals. Together with the collection of data on
antimicrobial sales and use per animal species under the new Regulation (EU) 2019/6 on veterinary
medicinal products, it will strengthen integrated analysis and help better target policy measures
promoting a prudent use of antimicrobials.
The Commission therefore needs first a comprehensive and global horizon screening, compilation
and scrutiny of available data on existing cases and experienced problems related AMR in bacteria
causing diseases in animals. Identification of lack of data, gaps and uncertainties is also important for
this part of the exercise. This may include knowledge on the characterisation of AMR mechanisms and
determinants responsible for the resistance in those bacteria.
Then the Commission needs advice specifically on the European dimension of the above global
state of play. This advice should identify bacteria, which could be considered in the EU for particular
attention by public authorities, animal keepers or other stakeholders alike, given their relevance. These
above may include both bacteria already included in the list provided by Annex II to the AHL and any
other animal bacteria.
Finally, the Commission needs scientific advice to decide which bacteria identified through the
above process, if any, may qualify to be listed in the AHL for EU regulatory measures (e.g. notification,
surveillance). This advice should be within the same framework of the already known listing and
categorisation according to the AHL, in the same way it was delivered based on previous respective
mandates. The criteria provided for in Articles 5, 7 and 8 and Annex IV of the AHL, shall be used as
the basis for this analytical assessment.
1.2. Terms of Reference as provided by the requestor
In accordance with Article 29 of Regulation (EC) No 178/2002, the Commission asks EFSA to
provide a scientific opinion on the following:
1. Global state of play as regards resistant bacterial animal pathogens that cause
transmissible animal diseases
To provide a state of play as regards AMR-related aspects in bacteria that cause transmissible
animal diseases in terrestrial, aquatic or other animals.9
In particular, EFSA should perform a literature review as follows:
• Review AMR-related aspects of any bacteria responsible for transmissible animal diseases for
which AMR concerns are described both at EU level and globally. This should include peer
reviewed scientific literature but not necessarily limited to that, it may also assess information
and data from other sources such as public/governmental sources, from livestock keepers or
their organisations, industry, etc.
• Target animal species should include terrestrial and aquatic food-producing animals subject to
farming in the EU, but also include companion animals, as there is a lack of data on AMR in
those species.
• The scope of the review should be limited to antimicrobial resistant bacteria that constitute a
threat to animal health, excluding bacteria covered by Directive 2003/99/EC.
• Based on the data available, the review should include a description of the occurrence and
prevalence of AMR in such bacteria, the most relevant antibiotics against which resistance has
developed and may also include other aspects such as the characterisation of the molecular
mechanisms responsible for such resistance. Identify the most significant resistant bacteria
causing disease in animals worldwide.
• Uncertainties and data gaps should be also identified and described.
2. Based on the global state of play established under point 1.
Summarise the situation in the EU in terms of the actual or potential impact on animal health of the
most relevant bacteria in the EU, indicating those for which sufficient data exist and those for which
data are not sufficient. EU relevance is to be understood on the basis of practical considerations, such
as actual presence in the EU or presence elsewhere but in animal species, age groups or production
systems which are widely used in the EU, or similar elements.
9 Animal categories as defined in points (2), (3) and (4) of Article 4 of Regulation (EU) 2016/429 (“Animal Health Law”).
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3. Listing and categorisation of bacteria identified under point 2 in the framework of the
Animal Health Law, where the available data seem to allow so:
3.1. Assess, following the criteria laid down in Article 7 of the AHL, their eligibility of being listed
for Union intervention as laid down in Article 5(3)(a) and (b)(ii) of the AHL;
3.2. If found eligible to be listed for Union intervention, provide:
1) an assessment of their compliance with each of the criteria in Annex IV to the AHL for the
purpose of categorisation of diseases in accordance with Article 9 of the AHL;
2) a list of animal species that should be considered candidates for listing in accordance with
Article 8 of the AHL.
1.3. Interpretation of the Terms of Reference
This section includes the interpretation of Terms of Reference (ToR) 1, ToR 2 and ToR 3 of the
mandate. Eight scientific opinions, one per host species or group of species (selected as explained
below), covering the objectives of ToR 1 and the first part of ToR 2 (identification of most relevant
bacteria in the EU) will be published following the methodology described in this Scientific Opinion.
Should approaches or methodologies deviate in certain host-specific assessments, deviations will be
described in detail in the corresponding scientific opinions.
To address the second part of ToR 2 (summarising actual or potential impact on animal health of
the most relevant bacteria in the EU) and ToR 3 of this mandate, a single opinion covering each of the
bacteria identified as relevant in the EU context in ToR 2 for all host species or group of species will be
published. The interpretation and methodology specific to this ToR 3 is as in Section 1.2 of the
Scientific Opinion on the ad hoc methodology followed for the assessment of the disease to be listed
and categorised according to the criteria of Article 5, Annex IV according to Articles 9 and 8 within the
AHL framework (EFSA AHAW Panel, 2017).
1.3.1. ToR 1: Global state of play as regards resistant bacterial animal
pathogens that cause transmissible animal diseases
In this first ToR, EFSA is requested to provide the state of play on AMR-related aspects in bacteria
that cause transmissible animal diseases in terrestrial, aquatic or other animals according to the animal
categories provided in Article 4 of the AHL. The scope of the mandate was limited to the following
species in agreement with the European Commission:
• Cats and dogs
• Horses
• Swine
• Poultry (including chicken, turkey, duck, goose, game birds and ratites)
• Cattle
• Small ruminants (sheep and goat)
• Rabbits
• Aquatic animals (tilapia, carp, rainbow trout, bream).
In terms of the bacteria causing transmissible diseases in these animal species, EFSA was
requested to exclude from this task zoonotic agents covered by Directive 2003/99/EC. Therefore, the
following species were not included in the global state of play: Borrelia spp., Brucella melitensis, B.
abortus, B. canis and B. suis, Campylobacter jejuni and Campylobacter coli, Chlamydia psittaci,
Clostridium botulinum, Leptospira spp., Listeria spp., Mycobacterium tuberculosis complex members,
Salmonella enterica, Verotoxigenic Escherichia coli, Vibrio spp. and Yersinia spp.
Furthermore, to define what was considered ‘a bacterium responsible for transmissible animal
diseases for which AMR concerns are described at EU level or globally’, the EFSA working group (WG)
agreed that:
only bacteria responsible for diseases that would trigger antimicrobial treatment, and for which
evidence on the existence of clinical or microbiological AMR was available, should be included in the
review.
Identification of such bacterial species was carried out through expert opinion (see Section 2.1.1).
Similarly, the list of antimicrobials used to treat the infection caused by the evaluated bacterial
pathogens was based on expert opinion and existing national antimicrobial guidelines, with a focus on
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those published by European Member States (see Section 2.1.3). Finally, to retrieve the information
that would allow to provide the global state of play, an extensive literature review that was then
subjected to the assessment of the WG was performed.
1.3.2. ToR 2: Identification of the most relevant bacteria in the EU (among
those included in ToR 1)
In the second ToR, EFSA is requested to summarise the actual or potential impact on animal health
in the EU of the most relevant bacteria among those identified in ToR 1, defining relevance on the
basis of practical considerations such as its actual presence in the EU, or elsewhere but in host
categories/production systems widely represented in the EU.
The practical considerations used by the WG were the frequency of the diseases caused by the
evaluated pathogens along with the frequency and geographic distribution of the AMR phenotypes
with a focus on antimicrobials used for their treatment. The actual or potential impact of the
antimicrobial resistant phenotypes of the bacteria (ARB) considered as ‘most relevant’ will be described
and summarised according to the criteria already laid down in the EFSA opinion ‘Ad hoc method for
the assessment on listing and categorisation of animal diseases within the framework of the Animal
Health Law’ (EFSA AHAW Panel, 2017) in which the impact on animal health has been defined by
morbidity and mortality rates of the disease in the animal population and the severity of clinical signs
at case level and related level and duration of impairment (table 3 in ref).
1.3.3. ToR 3: Listing and categorisation of bacteria identified under point 2 in
the framework of the Animal Health Law
The most relevant resistant bacteria identified in ToR 2 will then be further assessed within the AHL
framework. The AHL foresees the assessment of a disease/pathogen, based on the criteria listed in
Articles 5 (eligibility for listing), Article 9 (categorisation into control classes) and Article 8 (listing
species) performed on the basis of the information collected according to Article 7 (disease profile and
impacts). EFSA has already delivered several scientific opinions on the assessment of listing and
categorisation of animal diseases within the framework of the Animal Health Law and developed an ad
hoc methodology to guide the assessment (EFSA AHAW Panel, 2017). This ad hoc method will be
applied to assess the eligibility of the most relevant bacteria identified in ToR 2 for being listed for
European Union intervention (Article 5), their compliance with the criteria in Annex IV of the AHL for
categorisation (Article 9) and assess the host species to be considered candidates for listing (Article 8).
2. Data and methodologies
EFSA clarified with the requestor the terms of reference received; the outcome of this step is
reported in Section 1.2. Following clarification, the WG discussed the ToRs received from the requestor
to have a clear understanding of the outcome, the approach and the data needs by ToR. The
methodology laid down to answer each ToR is described in Sections 2.1, 2.2 and 2.3.
2.1. ToR 1: Global state of play as regards resistant bacterial animal
pathogens that cause transmissible animal diseases
The process to address ToR 1 was based on an extensive literature review (ELR) to identify AMR-
related aspects of relevant animal pathogens affecting terrestrial and aquatic food-producing and
companion animals in the EU as requested. To define the scope of the literature review, the following
steps were taken.
2.1.1. Definition of AMR concern
AMR concern for a given bacterial species in a given host species was defined as the existence of
either evidence of:
• Reduced in vitro susceptibility of a bacterium to antimicrobials of categories B, C and D as laid
down by the Antimicrobial Advice Ad Hoc Expert Group (AMEG) of the European Medicines
Agency (EMA) against which the bacterium is not naturally resistant;
• Reduced efficacy of antimicrobial treatment with antimicrobials of categories B, C and D of the
AMEG list against the disease caused by this bacterium in a host species of interest.
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Because the scope of this mandate only considers animal pathogens, it was the opinion of the WG
that only resistance to antimicrobials authorised for use in livestock and companion animals in the EU
were to be considered. Therefore, only antimicrobials included in the AMEG categories B (‘restrict’, use
restricted for treatment of clinical conditions in the absence of alternative clinically effective antibiotics
in lower categories and whenever possible based on results of antimicrobial susceptibility testing), C
(‘caution’, use when there is no available options in category D that would be clinically effective) and D
(‘prudence’, lowest risk to public health associated with their use in veterinary medicine, avoid
unnecessary use/unnecessarily long treatment periods) were considered (EMA, 2020). The
antimicrobials classes in these categories are listed in Table A.2 in Annex A. Resistance to category A
antimicrobials (‘avoid’, antimicrobial classes not authorised in veterinary medicine) were not in the
scope of the review.
Furthermore, it was agreed that focus should be made on antimicrobials that are important in
clinical practice for the treatment of the infections caused by each bacterial pathogen. Existing
treatment guidelines developed in European countries were used to advise the selection of these
‘important antimicrobials for clinical practice’.
2.1.2. Bacterial species to be included in the ELR
Given that the scope of the review should be limited to antimicrobial resistant bacteria that
constitute a threat to animal health, the WG experts drafted a list of bacterial species previously
described as causative agents of infectious diseases in each of the host species of interest based on an
informal review of the literature (without considering their clinical relevance). This process led to the
identification of between 27 and 77 known pathogen species for each host species or group of host
species (whole list of bacteria is reported in Appendix A).
Then, the known bacterial species that met one or more of the following conditions were excluded:
• The bacterium rarely causes diseases or production losses globally (i.e. where the bacterium is
present in the world);
• The bacterium never or rarely leads to an antimicrobial therapy;
• The bacterium never or rarely causes antimicrobial treatment failure due to AMR.
Wording of these conditions was chosen to ensure that bacterial pathogens that would be relevant
for the assessment were not excluded (i.e. maximised sensitivity of the approach at the possible cost
of including non-relevant bacteria at a first stage). The screening was performed first by the WG
members and then reviewed by a group of external experts in one or more of the host species of
interest that were contacted by EFSA (experts are reported in the Acknowledgement section). External
experts received the full list of bacteria for each host species and the preliminary assessment
performed by the WG, and were asked to provide their opinion on whether each bacterium complied
with each of the exclusion conditions stated above (possible answers: Yes/No/Unknown). The
understanding of the terms ‘never’ or ‘rarely’ was left to the appreciation of the experts.
Overall, 15 experts responded to the survey, although they did not always provide answers for all
host species (between four and eight external experts provided feedback for each host). Their answers
(along with those from WG members) were then combined to obtain an overall judgement for each
condition (Yes/No/Unknown).
Given that the objective of this process was to exclude only the bacterial species that were clearly
outside of the scope of the review, only those bacteria in which a majority (> 50%) of the experts
considered that it did not fulfil any of the exclusion criteria were deemed eligible. Obligate intracellular
pathogens (e.g. Anaplasma marginale, Coxiella burnetii) were in principle excluded from the scope of
the review due to the need to use cell models, which are time-consuming and labour intensive, to
determine their susceptibility in vitro and therefore the expected reduced evidence available to perform
a meaningful assessment of their AMR. The remaining list of pathogens was subjected to a second
review by the WG to exclude potentially non-relevant pathogens still included in the list by considering
the clinical relevance of the infection caused by each bacterium (i.e. removing bacterial pathogens with
little clinical importance based on expert opinion), and to include other pathogens initially excluded by
the external experts but deemed relevant by the WG.
The total number of bacteria that was finally included in the literature review ranged between 5
and 16 per host species (or group of host species) considered with the exception of aquatic species (in
this case only those bacteria for which international harmonised cut-off values for resistance exist,
were included) (CLSI, 2020) (Table 1). The full list of pathogens screened is reported in Appendix A.
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Table 1: List of bacterial pathogens included in the literature review for each host species or group
of species. Animal-associated pathogenic bacteria are defined based on the origin of
clinical isolates
Host Bacterial species
Cats and dogs (n = 13) Bordetella bronchiseptica Klebsiella pneumoniae
Clostridium difficile Proteus mirabilis
Clostridium perfringens Pseudomonas aeruginosa
Enterobacter spp. Staphylococcus aureus
Enterococcus faecalis Staphylococcus pseudintermedius
Enterococcus faecium Staphylococcus schleiferi
Escherichia coli
Horses (n = 12) Actinobacillus equuli Pseudomonas aeruginosa
Dermatophilus congolensis Rhodococcus equi
Enterococcus spp. Staphylococcus aureus
Escherichia coli Streptococcus dysgalactiae
Klebsiella pneumoniae Streptococcus equi equi
Pasteurella spp. Streptococcus equi zooepidemicus
Swine (n = 16) Actinobacillus pleuropneumoniae Mycoplasma hyorhinis
Bordetella bronchiseptica Mycoplasma hyosynoviae
Brachyspira hyodysenteriae Pasteurella multocida
Brachyspira pilosicoli Staphylococcus aureus
Erysipelothrix rhusiopathiae Staphylococcus hyicus
Escherichia coli Streptococcus dysgalactiae
Glaesserella (Haemophilus) parasuis Streptococcus suis
Mycoplasma hyopneumoniae Trueperella pyogenes
Poultry (n = 14) Avibacterium paragallinarum Gallibacterium anatis
Bordetella avium Mycoplasma gallisepticum
Clostridium perfringens Mycoplasma synoviae
Enterococcus cecorum Ornithobacterium rhinotracheale
Enterococcus faecalis Pasteurella multocida
Erysipelothrix rhusiopathiae Riemerella anatipestifer
Escherichia coli Staphylococcus aureus
Cattle (n = 12) Escherichia coli (non-VTEC) Mycoplasma bovis
Fusobacterium necrophorum Pasteurella multocida
Histophilus somni Staphylococcus aureus
Klebsiella pneumoniae Streptococcus dysgalactiae
Mannheimia haemolytica Streptococcus uberis
Moraxella bovis Trueperella pyogenes
Sheep and goats (n = 16) Bibersteinia trehalosi Mycoplasma capricolum capricolum
Campylobacter fetus Mycoplasma mycoides capri
Dichelobacter nodosus Mycoplasma ovipneumoniae
Escherichia coli (non-VTEC) Pasteurella multocida
Fusobacterium necrophorum Pseudomonas aeruginosa
Mannheimia haemolytica Staphylococcus aureus
Moraxella ovis Streptococcus uberis
Mycoplasma agalactiae Trueperella pyogenes
Rabbit (n = 5) Bordetella bronchiseptica Pseudomonas aeruginosa
Escherichia coli Staphylococcus aureus
Pasteurella multocida
Aquatic species (n = 4) Aeromonas hydrophila Flavobacterium columnare
Aeromonas salmonicida Flavobacterium psychrophilum
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2.1.3. Clinically relevant antibiotics
The antimicrobials included in the ELR were chosen among categories B, C and D, as laid down by
the AMEG of the EMA (EMA, 2020). For each animal species/bacterial pathogen combination, relevant
antimicrobials for veterinary therapy were selected, according to existing treatment guidelines from
European countries and expert opinions. Each time, selected antimicrobials included first-line treatment
options, as well as second- or third-line alternatives, even when experts were not aware of any
resistance being described for the selected antimicrobials.
2.1.4. Extensive literature review (ELR)
The question posed in the ELR was:
‘For which of the bacteria listed, is there evidence of acquired clinical resistance and/or reduced
susceptibility to antimicrobial classes included in categories B, C or D defined by the Antimicrobial
Advice ad hoc Expert Group (AMEG) of the European Medicines Agency (EMA) and recommended for
treatment of the infection caused by them?’
To perform the task, the question was split into three subquestions that were used to build the
search strings:
1) Does resistance to ANTIMICROBIAL DRUG NAME occur in BACTERIAL SPECIES NAME
isolated from ANIMAL SPECIES NAME?
2) What is the frequency of resistance to ANTIMICROBIAL DRUG NAME in BACTERIAL SPECIES
NAME isolated from ANIMAL SPECIES NAME?
3) Does resistance to ANTIMICROBIAL DRUG NAME in BACTERIAL SPECIES NAME cause
treatment failure in ANIMAL SPECIES NAME?
Each of the searches was conducted separately for each host species/group of species, considering
only the corresponding bacterial species listed in Section 2.1.2 as candidates. The ELR was limited to
articles published after 2010, as the objective was to provide updated information that would describe
the current global state of play, and was run on two international article databases, Web of Science
(https://apps.webofknowledge.com/) and PubMed including Medline (https://www.nlm.nih.gov/bsd/
pmresources.html).
To obtain data with sufficient quality to be used in the assessment, the following exclusion criteria
were applied, mostly related to the way in which data on AMR were provided/summarised in the
retrieved articles:
1) Data are provided in a way that does not allow one to differentiate between antimicrobial
drugs (e.g. a study reports simply the antimicrobial class ‘fluoroquinolones’). One exception
is if the study lists the antibiotic tested in M&M (e.g. ‘enrofloxacin’) but reports data at class
level (‘fluoroquinolone’).
2) AMR data are reported together for different animal species.
3) Data are reported at the bacterial genus level. Exceptions exist for bacteria often reported
at the genus level and when species within the genus have the same breakpoints (e.g.
Enterococcus, Klebsiella, Pseudomonas, Proteus).
4) Study is conducted not using a standard for antimicrobial susceptibility testing (AST), or a
standard is not reported (CLSI, EUCAST or National Standards accepted).
5) The study provides results from non-clinical isolates (i.e. from non-clinically affected
animals), or it is not possible to differentiate between clinical and non-clinical isolates.
6) The same individual is deliberately sampled multiple times.
7) The percentage of resistant isolates is not reported (e.g. data shown in bar charts instead).
8) Less than a minimum number of isolates are included in the study. This number may vary
depending on the bacterial species (e.g. it can be as high as 50 in studies for
Staphylococcus spp. and E. coli, in which a large number of references are expected, and
lower for others). In any case, all studies including less than 10 isolates are excluded.
9) AMR data from the same isolates are included in another selected study (data duplication or
a review article).
10) Full text not available from searches using the journal subscriptions of the University of
Copenhagen.
11) Articles are published in a language other than English.
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12) Minimum inhibitory concentration (MIC) data are reported without interpretation into
susceptible/resistant.
13) Antimicrobials included in the study are not routinely used for treatment in the host species
based on available treatment guidelines.
14) The criteria for selection of the isolates are unclear and the risk of data duplication is high
(e.g. studies testing diagnostic methods, comparing AST methods, defining clinical
breakpoints or investigating pharmacodynamics of specific antimicrobial drugs).
15) All isolates in a study originate from the same farm or premises.
16) AMR was assessed only genotypically.
17) Other exclusion criteria (to be specified when appropriate).
These exclusion criteria could be modified, however, when considered appropriate in running the
literature searches of specific host species (e.g. criterion 2: articles reporting data from isolates
retrieved from cats and dogs without differentiating the source were considered eligible; criterion 16:
studies in which the presence of the mecA gene was used to infer prevalence of methicillin-resistant
Staphylococcus aureus, S. pseudintermedius were considered eligible). These modifications of the
standard methodology will be reported in the scientific opinions devoted to each host species/group of
species.
The data extracted from the selected articles included the number of isolates tested, their origin
(e.g. type of sample from which they were isolated) when available, the number/proportion of isolates
that was resistant to each antimicrobial tested among those considered of interest for the pathogen/
host combination, and the interpretation criteria used to define resistance (clinical breakpoints or
epidemiological cut-off values (ECOFFs)). This was used to produce a report summarising the results
found in the ELR and tables reporting the raw extracted data. Further details on the protocol followed
in the ELR can be found in Annex A. In addition, national AMR surveillance reports from EU countries
including AMR data from clinical pathogens retrieved from the animal species of interest for this
mandate will be also screened for eligibility using the same set of exclusion criteria as above.
2.2. ToR 2: summary of the situation in the EU in terms of actual or
potential impact on animal health of the most relevant bacteria in
the EU
2.2.1. Assessment of the most relevant bacteria in the EU
The outcome of the ELR was used to first identify, among the screened bacterial species, the most
relevant ones for the EU based on:
• the frequency of AMR in the bacterium (considering also the clinical relevance of the pathogen,
number of publications – and isolates included in those publications – reporting the presence
of resistant phenotypes, and the geographic distribution of the resistant isolates);
• availability of therapeutic options (range of antimicrobials to treat the infection and importance –
first/second/third line – of the antimicrobials against which the bacteria were resistant).
Each WG member made an individual judgement on whether each of the bacterial species assessed
in ToR 1 were among the ‘most relevant’ ones for a given host or not, or it was ‘unclear’, based on the
evidence retrieved in the ELR, along with the rationale supporting their judgement. Individual
judgements were then discussed at a WG meeting. Bacteria unanimously judged as ‘most relevant’
were automatically included in the following phase of the assessment (actual or potential impact on
animal health under ToR2, and listing and categorisation under ToR 3), while those in which there was
disagreement were subjected to further discussion until a consensus agreement was reached as to
whether it should be included among the ‘most relevant’ category or not. Pathogens excluded from the
‘most relevant’ ones were further categorised based on their importance when possible according to
the information available based on the evidence gathered and on the expert opinions (e.g. a higher
number of studies/isolates tested was considered suggestive of higher clinical relevance of the
pathogen and of resistant phenotypes).
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2.2.2. Summary of the actual or potential impact on animal health in the EU of
the most relevant bacteria
The actual or potential impact of the antimicrobial resistant bacteria considered as ‘most relevant’
will be described and summarised according to the criteria already defined in the EFSA opinion ‘Ad hoc
method for the assessment on listing and categorisation of animal diseases within the framework of
the Animal Health Law’ (EFSA AHAW Panel, 2017).
2.3. ToR 3: Listing and categorisation of bacteria identified under point
2 in the framework of the Animal Health Law
The objective of this ToR is to assess the eligibility of the most relevant bacteria identified in ToR 2
for being listed for European Union intervention (Article 5), their compliance with the criteria in Annex
IV of the AHL for categorisation (Article 9) and assess the host species to be considered candidates for
listing (Article 8). To carry this out, EFSA will follow the ad hoc method for the assessment on listing
and categorisation of animal diseases within the framework of the Animal Health Law (EFSA AHAW
Panel, 2017) developed in 2017 and implemented to perform the assessment of several animal
diseases within the AHL framework (EFSA, online).
2.4. Uncertainty analysis
Several possible sources of uncertainty associated with different steps in the proposed methodology
were identified:
• First, the initial list of pathogens was drafted through a non-systematic literature review, and
therefore, there is a risk of both missing relevant pathogens and including pathogens non-
relevant for this assessment.
• Second, although this list was further refined based on expert opinion to keep only pathogens
that were relevant for the assessment in the ELR (global state of play as regards resistant
bacteria), experts providing feedback mostly originated from the EU, and expertise was more
limited for certain hosts or groups of hosts (e.g. only four external experts provided feedback
for a subset of the pathogens initially considered for rabbits and aquatic animals).
• Third, the global state of play described in the host-specific scientific opinions as well as the
identification of the most relevant bacteria for each host or group of hosts was carried out
based on a ELR with a limited scope (e.g. only studies published in the last 10 years, in English
or including some isolates – 10–50 depending on the bacterial pathogens – were included). It
is therefore possible that we missed relevant literature not captured by the selection criteria
defined for the ELR.
• Fourth, only resistance to antimicrobials in AMEG categories B, C and D was initially considered
when defining AMR concern, since these are the only categories that are authorised for use in
livestock and companion animals in the EU. However, resistance to other antimicrobials (AMEG
category A) may also potentially influence or be associated with resistance to the selected
antimicrobials (due to e.g. co-selection phenomena). Furthermore, even though available
antimicrobial usage guidelines will be used to select the antimicrobials against which resistance
will be assessed in the ELR, it is possible that certain antimicrobials that may be used to treat
an infection by a given pathogen worldwide may be left out from the assessment.
• Fifth, since evidence retrieved originates primarily from studies published in the scientific
literature, there is a risk of publication bias affecting the results found in the ELR (e.g. in
favour of studies reporting higher levels of resistance).
• Finally, even though there was consensus on the criteria to consider for the identification of
the ‘most relevant’ ARBs, and the literature review provided useful evidence on resistance
proportions, the selection of the ‘most relevant’ ARBs was also based on expert opinion, as the
lack of evidence obtained through unbiased and systematic methodologies would not allow
using common or even host-specific thresholds for frequency of resistance in a given
pathogen, geographical spread, etc.
Uncertainties derived from the data and the methodology used in the assessment could impact the
conclusions in two ways:
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• Certain ARBs could be wrongly included among the ‘most relevant’ ones for a given host (‘false
positive’).
• Certain ARBs could be wrongly excluded from the ‘most relevant’ category for a given host
(‘false negative’).
The probability of occurrence of false-positive or false-negative ARBs in the assessment was
quantified collectively by expert judgement at the WG meetings taking into account all identified
uncertainties. The impact of the sources of uncertainty that were identified on the final results of the
scientific assessment was evaluated collectively by the WG using approximate probabilities (e.g.
Table 2). Experts first provided individual judgements that were then discussed, and a consensus
judgement was obtained.
3. Conclusions
An ad hoc method for the assessment of animal diseases caused by bacteria resistant to
antimicrobials was developed by the EFSA WG. The assessment methodology includes: (i) the
procedure to identify the antimicrobial-resistant bacteria that may constitute a threat to animal health
and the respective clinically relevant antimicrobials, (ii) the definition of the protocol to carry on an ELR
to give a global state of play of those resistant bacteria and (iii) the procedure to carry on an expert
judgement to identify the most relevant resistant bacteria in the EU.
This ad hoc method allowed the WG to identify between 5 and 16 ARB that constitute a threat to
animal health in cats and dogs, horses, swine, poultry, cattle, small ruminants and rabbits, plus four
ARB for aquatic animal species (the identified bacteria are reported in Table 1). A global state of play
of those bacteria and a further assessment to identify those that might be considered as most relevant
in the EU will be performed according to the method here presented. The assessment results will be
published in a separated opinion, one for each host species (or group of host species).
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Appendix A – List of bacteria of interest by animal species presented in
alphabetical order, indicating whether they were selected for inclusion or
not
Cats and dogs
























Campylobacter spp. (upsaliensis and helveticus) No





Ehrlichia spp. (ewingii, chaffeensis, muris) No
Francisella tularensis No











Table A.1: List of bacteria by animal species of interest sorted by included (in green) and not
included (in grey) pathogens and alphabetical order (initial list and bacteria selected for
the literature search)
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Bacterium Included in assessment?
Rickettsia spp. (felis, conorii, rickettsii) No
Staphylococcus spp. (CoNS) No
Horses










Streptococcus dysgalactiae subsp dysgalactiae/equisimilis Yes
Streptococcus equi ssp. equi Yes




























Bacterium Included in assessment?
Actinobacillus pleuropneumoniae Yes
Arcanobacterium pyogenes (Trueperella pyogenes) Yes
Bordetella bronchiseptica Yes
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Bacterium Included in assessment?




























Mycoplasma capricolum ssp. capricolum Yes
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Mycobacterium avium ssp. paratuberculosis No
Mycoplasma arginini No





































Mycobacterium avium ssp. paratuberculosis No
Neisseria sp. No
Assessment of animal diseases caused by bacteria resistant to antimicrobials: ad hoc method
www.efsa.europa.eu/efsajournal 21 EFSA Journal 2021;19(6):6645
Bacterium Included in the assessment?
Stomatococcus sp. No
Streptococcus sp. (S. pyogenes) No
Treponema paraluiscuniculi No
Aquatic animals: only bacterial species for which international harmonised cut-off values for
resistance exist were included
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Annex A – Protocol for the Extensive Literature Review
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A.1. Description of the task
The task is to carry out an Extensive Literature Review (ELR) to answer the epidemiological
question: For which of the bacteria listed in Table A.1, is there evidence of acquired clinical resistance
and/or reduced susceptibility to antimicrobial classes included in Categories B, C or D defined by the
Antimicrobial Advice ad hoc Expert Group (AMEG) of the European Medicines Agency (EMA)? The ELR
is expected to gather the relevant literature to answer this question with particular regard to
occurrence, frequency and geographical distribution of AMR at the global level for each bacterial
species listed in Table A.1. The team at the University of Copenhagen (UCPH) will carry out this task
according to the time plan agreed with EFSA, and will deliver a separate ELR for each of the following
animal species/groups:
• Dogs and cats (ELR 1)
• Horses (ELR 2)
• Pigs (ELR 3)
• Poultry (chicken and turkey, duck, goose, game bird, ratites (ELR 4)
• Cattle (ELR 5)
• Sheep and goats (ELR 6)
• Rabbit (ELR 7)
• Aquatic animals (ELR 8)
The task includes the following three subtasks:
Task 1 – Develop a tailored search strategy (including terms and strings as well inclusion/exclusion
criteria) for answering the question mentioned above.
Task 2 – Carry out an ELR using the search strategy and following the protocol described in this
document.
Task 3 – Extract and synthetise the data retrieved by each ELR.
A.2. Review questions
Clear review questions are indispensable to perform this work since AMR is a generic term that
requires contextualisation (i.e. animal species, bacterial species/genus and antimicrobial drug name).
Accordingly, we propose to split the question of Task 1 into three questions:
1) Does resistance to ANTIMICROBIAL DRUG NAME occur in BACTERIAL SPECIES NAME isolated
from ANIMAL SPECIES NAME?
2) What is the frequency of resistance to ANTIMICROBIAL DRUG NAME in BACTERIAL SPECIES
NAME isolated from ANIMAL SPECIES NAME?
3) Does resistance to ANTIMICROBIAL DRUG NAME in BACTERIAL SPECIES NAME cause
treatment failure in ANIMAL SPECIES NAME?
A.3. Eligibility criteria
Inclusion criteria (before full-text review):
• Bacterial species/genus: only bacterial species and genera listed in Table A.1.
• Antimicrobial drug: only antimicrobial classes belonging to categories B, C or D in the AMEG
classification.
• Publication year: only articles, reports, etc. published between 2010 and 2020.
• Language and accessibility: only publications in English available in full text from the UCPH
server.
• Type of study: any in vitro studies providing phenotypic data on antimicrobial susceptibility
testing or genotypic data on presence/absence of AMR genes.
Exclusion criteria (may be applied during abstract screening, but often not possible to follow
before full-text review):
• Not possible to differentiate between antimicrobial drugs (e.g. a study reports antimicrobial
classes ‘fluoroquinolones’). One exception is if the study lists the antibiotic tested in M&M (e.g.
‘enrofloxacin’) but reports data at class level (‘fluoroquinolone’).
• AMR data are reported together for different animal species (exception: dog/cat and
sheep/goat may be reported together).
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• Data reported at the genus level. Exceptions exist for bacteria often reported at the genus
level and where species within the genus have the same breakpoints (e.g. Enterococcus,
Klebsiella, Pseudomonas, Proteus).
• Not using a standard for AST or standard not reported (CLSI, EUCAST or National Standards
accepted).
• Not clinical isolates, or not able to differentiate between clinical and non-clinical isolates
• Same individual deliberately sampled multiple times.
• No % resistant reported (e.g. data shown in bar charts instead).
• Less than 10 isolates in a study. NB: in order to increase quality of extracted data, this lower
may be increased for some commonly occurring pathogens, e.g. Staphylococcus spp and
E. coli.
• AMR data from the same isolates are included in another selected study (data duplication or a
review).
• Full text not available from searches using the journal subscriptions of the University of
Copenhagen.
• Non-English.
• MIC data reported without interpretation into susceptible/resistant.
• Antibiotics reported are not routinely used for treatment in the host species based on available
treatment guidelines (list of clinically relevant antibiotics is made and agreed upon with the
EFSA WG before extraction of data).
• Studies where the criteria for selection of the isolates are unclear and the risk of data
duplication is high (e.g. studies testing diagnostic methods, comparing AST methods, defining
clinical breakpoints or investigating pharmacodynamics of specific antimicrobial drugs).
• All isolates in a study originate from the same farm/house.
• Studies where AMR was only assessed genotypically except those where mecA was used to
infer MRSA/MRSP prevalence.
• Other (reasons to be added in Excel file).
Outcome measures:
• AMR occurrence (yes/not) and AMR frequency/prevalence, which is usually reported as a
fraction or percentage (e.g. number of resistant isolates divided by the total number of isolates
tested).
A.4. Information sources
Two international article databases, EMBASE and PubMed, will be searched using the search
strategy described in Section A.5. To minimise the risk of data duplication, grey literature will be
limited to reports from national or international AMR surveillance programmes.
A.5. Search strategy
Search strategies were developed to address the specific questions formulated in Section A.2 for
each of the bacterial species listed in Table A.1 of this Appendix. All searches were performed in
PubMed and Embase databases. For each database and animal species, we introduced terms that
targeted (i) antimicrobial agents, (ii) resistance/susceptibility, (iii) animal host and (iv) bacterial
pathogen. In PubMed, each term was included as a title/abstract term and as a subject heading
(MeSH) term (if available). Review papers and publications prior to 2010 were excluded from the final
search. In Embase, each term was included as a multi-purpose term (mp=title, abstract, heading word,
drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword,
floating subheading word, candidate term word) and as a subject heading term (if available). For each
independent term searched as a subject heading, narrower terms were examined, and specific
narrower terms may have been included if relevant. In lack of specific terms as subject headings,
broader terms were also examined and included if relevant and if the search did not broaden to other
pathogens not aimed for (e.g. we included the subject heading term ‘Lawsonia bacteria’ instead of
‘Lawsonia intracellularis’, which did not exist as a subject heading). Detailed search strings will be
provided in the separate reports (D1.2) for each animal investigated.
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Although the above search string does not contain terms related to treatment outcome, we believe
that papers on that topic (Type B studies) will also appear from the string. After all, treatment
outcome has to be linked to data on antimicrobial susceptibility.
A.6. Data management
The results of search engines will be downloaded and load them into the Rayyan software (https://
libraryguides.mcgill.ca/rayyan/gettingstarted). Duplicate elimination and selection based on title/
abstract will be performed in Rayyan. The final list of publications that will be checked in full text can
be exported from Rayyan in RefMan, BibTex, EndNote or csv formats, which can be shared between
reviewers.
A.7. Selection process
The initial selection process will be executed by a reviewer with expertise in AMR. In the first
instance, abstracts and titles will be screened according to the inclusion criteria listed in Section A.3.
The reviewer will evaluate each reference for relevance using the following sequence of questions:
1) Does the title or abstract refer to in vitro phenotypic or genotypic data on AMR/susceptibility in
relevant bacterial species/genus?
Yes ? Include for full-text assessment
No ? Exclude
Following title/abstract screening, the selected studies will be included in the ELR when appropriate.
The full text of the potentially relevant publications will be retrieved and assessed for compliance to
the eligibility criteria listed in Section A.3. Only references passing this assessment step will be included
in the data extraction.
Identification and deletion of duplicate data, i.e. data that have been included in multiple
publications. Methods to help identify duplicated data:
1) Trial identification numbers (e.g. ClinicalTrials.gov Identifier (NCT number); ISRCTN; Universal
Trial Number (UTN); other identifiers such as those from the sponsor.
2) Author names.
3) Location and setting.
4) Specific details of the interventions (e.g. dose, frequency).
5) Numbers of participants and baseline data.
6) Date and duration of the study which can also clarify whether different sample sizes are due
to different periods of recruitment.
The selection process is a very critical step since relevant studies and useful data might be lost due
to human errors or methodological inaccuracies. The quality assurance methods that we propose to
minimise this risk are described in Section A.10.
A.8. Data extraction
The data extraction process will be performed by a dedicated ‘data extractor’. Data will be
transferred to an electronic database extraction form shared by data reviewers in Google Sheets. The
number of free text fields will be limited as much as possible to simplify data analysis. This data
extraction form, or an extraction thereof into a table format, will function as deliverable D1.3.
For each paper deemed to meet the criteria for inclusion, the information mentioned in
Section A.10 will be extracted.
A.9. Data synthesis
Data extracted from the included studies for each animal species will be summarised in a summary
report. This narrative synthesis will be used to highlight key differences between the studies in relation
to study design, population, methodology, etc. as well as to assess their methodological quality. For
each animal species, the studies will be grouped by production type, bacterial pathogen and outcome
measure, since it does not make sense to compare AMR studies that differ in relation to these factors.
The results will be tabulated in a summary table including results separated by relevant groups (e.g.
age groups, disease type), and add comments concerning relevant methodological differences
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between studies, or differences in the populations studied. The report will highlight knowledge gaps,
and potential biases in the review process will be evaluated, i.e. if the methods used to perform the
review and the assumptions made to analyse the data may have affected the results.
A.10. Quality assurance
The following measures will be taken to ensure quality and reduce bias or human errors during the
critical steps of the review process.
Selection of studies
• Studies will be selected according to the inclusion and exclusion criteria described in
Section A.3.
• The selection process will be described in the summary report including a description of the
main reasons for exclusion of studies after full-text screening.
Data extraction
• A data extraction form implementing the key points in Section A.10 will be used to ensure
consistency, and improve validity and reliability of the extraction process.
• The data extraction form will be piloted on a sample of included studies to ensure that all the
relevant information is captured and that resources are not wasted on extracting data that are
not required.
• To minimise data extraction errors and ensure a sufficient and harmonised level of detail,
reviewers will regularly check the data extractors’ input to the data extraction form. If
disagreements occur between the reviewers and data extractors, they will be resolved using a
consensus-based approach after discussing disagreements.
Assessment of study quality
• The reviewers will assess – individually and through discussion with relevant experts in the
consortium – the risk of bias caused by inadequacies in study design, conduct or analysis that
may lead to errors in the measurement or misinterpretation of antimicrobial susceptibility data
(type A studies), or to over/underestimation of the treatment outcome (type B studies).
• It will be noted for each study whether the research question was stated clearly or not.
• It will be assessed if the population of a study was clearly specified and defined. In order to
assess that somewhat objectively, studies will be divided into i) those with isolates deriving
from a clearly defined population of animals in a clinic, hospital, farm or similar (e.g. kennel),
and ii) those from a diagnostic laboratory with a non-defined population (i.e. without
background information on patients).
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Table A.2: AMEG categorisation of antimicrobials classes
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A.11. Key points in planning data extraction
The following information will be extracted and typed into an Excel sheet for publications/reports
selected for full-text evaluation:
o Study ID
o Initials of person screening full text
o Decision to include or not
• Specifically for excluded studies:
o Reason(s) for exclusion
• Specifically for included studies:
o Whether the research question was clearly stated or not
o Study population category:
▪ 1: Clinic/hospital/farm
▪ 2: Diagnostic lab (i.e. unknown population)
o If the study provided raw data (e.g. MIC data)
o Method for detection/quantification of resistance





o How the intermediate category was reported/used
o Organ
o Antibiotic
o Number of isolates
o % resistant isolates
o % intermediate isolates
o % intermediate + resistant isolates
o Reference for breakpoint used or epidemiological cut-off used
o Various notes to explain data (when needed)
Other variables may be added ad hoc for specific animal species, e.g. ‘production type’ (e.g. dairy/
meat/egg) and ‘production system’ (e.g. conventional/organic) will be relevant for food-producing
animals but not for companion animals.
The ‘Year’ of bacterial isolation will not be neither extracted nor reported from the studies included,
as in most studies, the isolates had been collected over several years with no specification on the
number of isolates per year.
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